GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » ROC (Joel Greenblatt) %

Azenta (Azenta) ROC (Joel Greenblatt) % : -26.56% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Azenta ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Azenta's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -26.56%.

The historical rank and industry rank for Azenta's ROC (Joel Greenblatt) % or its related term are showing as below:

AZTA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -34.47   Med: -2.98   Max: 15.88
Current: -9.89

During the past 13 years, Azenta's highest ROC (Joel Greenblatt) % was 15.88%. The lowest was -34.47%. And the median was -2.98%.

AZTA's ROC (Joel Greenblatt) % is ranked worse than
54.24% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: 0.48 vs AZTA: -9.89

Azenta's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Azenta ROC (Joel Greenblatt) % Historical Data

The historical data trend for Azenta's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta ROC (Joel Greenblatt) % Chart

Azenta Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.47 -17.88 -15.32 -0.93 -5.03

Azenta Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.52 -4.86 -3.66 -5.71 -26.56

Competitive Comparison of Azenta's ROC (Joel Greenblatt) %

For the Medical Instruments & Supplies subindustry, Azenta's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azenta's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Azenta's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Azenta's ROC (Joel Greenblatt) % falls into.



Azenta ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(156.535 + 128.198 + 116.44) - (124.696 + 52.321 + 33.911)
=190.245

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(155.926 + 127.184 + 115.556) - (144.007 + 58.245 + 33.368)
=163.046

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Azenta for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-102.228/( ( (205.744 + max(190.245, 0)) + (210.628 + max(163.046, 0)) )/ 2 )
=-102.228/( ( 395.989 + 373.674 )/ 2 )
=-102.228/384.8315
=-26.56 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Azenta  (NAS:AZTA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Azenta ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Azenta's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Azenta (Azenta) Business Description

Traded in Other Exchanges
Address
200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
Executives
Herman Cueto officer: EVP, Chief Financial Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes officer: VP, Chief Accounting Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray officer: Chief Strategy & New Business C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin director
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne officer: SVP and GM, Life Sciences Proj 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou officer: SVP and General Manager, Genom 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus officer: EVP & Chief Operating Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson officer: EVP & Chief Financial Officer C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley officer: Chief Human Resources Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram officer: VP, Finance & Corp. Controller 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De officer: Chief Commercial Officer, LS 15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka officer: Sr. VP, General Manager 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha officer: SVP, GM BLS-Products 15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824